GenSight Biologics Plans Financing for RECOVER Phase 3 Trial

PUBT · 2d ago
GenSight Biologics Plans Financing for RECOVER Phase 3 Trial
  • GenSight Biologics plans to use approximately EUR 1.05 million in net fundraising proceeds for operating activities and working capital.
  • The financing extends funding through late March 2027, subject to French early-access patient volumes meeting estimates.
  • Preparations continue for structural financing of the RECOVER Phase 3 trial, with initial significant preparation payments due in late March 2027.
  • GS010/LUMEVOQ will remain available through early access while regulatory agency interactions approach.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gensight Biologics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261119658009) on November 20, 2026, and is solely responsible for the information contained therein.